Chief Development Officer

Dr. Tuvia is a senior biopharmaceutical executive with >25-years of experience. Before co-establishing INDoors Medical Development, he served as Chief Scientist Officer at the clinical-stage oncology company Ayala Pharm (NASDAQ:ADXS), Chief Development Officer at Ukko, developing building a comprehensive, clinically validated map of the molecular structure of food allergies, Chief Innovation Officer at FutuRx, an incubator, founded by J&J, Takeda, and OrbiMed, the Chief Operating Officer at Eloxx (NASDAQ:ELOX) that develops novel small molecule medicines to treat rare and ultra-rare genetic diseases, Vice President Preclinical at Chiasma Pharmaceuticals (NASDAQ: CHMA), where he headed preclinical development and pharmacology of oral octreotide through the NDA submission (Mycapssa®). Dr Tuvia earned his MSc and BSc degrees in biology from Tel-Aviv University, Israel, and his Ph.D. with Distinction at the Sackler School of Medicine at Tel-Aviv University, Israel and postdoc studies at Duke University. He is a co-author of 20 peer reviewed publications and co-inventor of 12 patents